Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · STAAR Surgical (STAA)

STAAR Surgical Q3 net sales fall 12% to $83.4 million; net income $5.6 million

Mixed Impact 3 of 5 earnings

STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, down 12% from $94.7 million a year earlier, and net income of $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18, in the prior-year quarter. The prior-year quarter included $25.9 million of deferred China sales; excluding that, third-quarter net sales rose 21%, and the company said it expects gross margin to improve in the fourth quarter. The Board also authorized a share repurchase of up to $50 million, and the company reported no outstanding debt.

Key points

  • Net sales were $83.4 million, down 12% from $94.7 million; up 21% excluding $25.9 million of deferred China sales recognized in the third quarter of 2025.
  • Gross profit margin was 70.9%, compared with 82.2% in the prior-year quarter, which included deferred China revenue with no cost of sales.
  • Net income was $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18, a year earlier.
  • In September 2026 the Board authorized repurchases of up to $50 million of common stock; cash and investments were $206.4 million as of October 2, 2026, with no outstanding debt.

The filing

CompanySTAAR Surgical (STAA)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:03 PM ET
Accession number0000718937-26-000040

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.